LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent
pulmonary injury when administered early in hospital course to the patients at risk for
developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for
budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (COPD),
but the use of these two drugs is experimental for ARDS.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Beth Israel Deaconess Medical Center National Center for Research Resources (NCRR) Stanford University University of Arizona